At A Glance:

This sponsor was in a crucial race in the diabetes space as it began Phase III clinical trials for a new class of drug for type 2 diabetes. They were rolling into a crowded field of companies developing competitive compounds.

Download PDF
Indication:

Type 2 Diabetes

Enrollment time saved: 256 days
See the results
Case Study

AES Shortens Timelines by up to 20 Months for a Uterine Fibroid Program

VIEW CASE STUDY >
Case Study

AES saves up to 76 months of enrollment time for this pediatric depression program

VIEW CASE STUDY >
Case Study

Thanks to AES, a Sponsor Won its Race to Market with a New Class of OIC Drug

VIEW CASE STUDY >
Case Study

AES Shortens Enrollment by 7 Months for a Crucial Migraine Phase IIb Study

VIEW CASE STUDY >
Case Study

AES Saves More than 4 Months of Enrollment Time and $2.2 Million for Phase III Atopic Dermatitis Study

VIEW CASE STUDY >